Clinical Trial · NCT06995976

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Overview

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Sponsor

First Affiliated Hospital of Fujian Medical University

Phase

Early Phase 1

Contacts

Rong Lin, MD (CONTACT)

linrong1214@foxmail.com

+86-0591-87981619

Weibing Miao, MD (CONTACT)

miaoweibing@126.com

+86-0591-87981618

Weibing Miao, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06995976

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

dPNE

Isotope(s):

Target(s):

CD73

Ligand Class: Small Molecules

Chelator: DOTA